Journal of Preventive Cardiology
Current Issue

Review Article

Year: 2016 I  Volume: 6I  Issue: 1I  Pages:954–961

Dyslipidemia in children and adolescents

Dr. Peeyush Jain*, MBBS, MD (Med), DM (Cardiology); Sitaraman Radhakrishnan†, MBBS, MD (Med),
DM (Cardiology); Dr. Ashok Seth‡, FRCP (London),
FRCP (Edinburgh), FRCP (Ireland), FACC, FESC, FSCAI (USA), FIMSA, FCSI,
D.Sc. (Honoris Causa), D.Litt (Honoris Causa)
*Director (Cardiology) and Head, Department of Preventive Cardiology, Fortis-Escorts Heart Institute, New Delhi, India
†Director, Department of Pediatric and Fetal Cardiology, Fortis-Escorts Heart Institute, New Delhi, India
‡Chairman, Fortis Escorts Heart Institute; Chairman, Cardiology Council, Fortis Group of Hospitals; Past President, Cardiological Society of India; Vice President, Asian Pacific Society of Cardiology, Member, Medical Council of India



Some children have genetically determined dyslipidemias that predisposes them to early heart attacks. In addition, dyslipidemias associated with obesity and diabetes mellitus are being increasingly recognized in children and adolescents. Postponing treatment of severely elevated cholesterol until middle-age or late adulthood in both situations may be too late for some children. It is now recommended that all children should be screened for lipids between ages 9 and 11 years and once again between ages 17 and 21 years. Selective screening in other age groups may be desirable if childhood hypertension, diabetes, or obesity is present. Evaluation for a cause is necessary in children with abnormal lipid levels. Severe elevation is likely to be genetic in origin. The mainstay of treatment of high cholesterol levels in children and adolescents is diet and physical activity. No dietary restriction is recommended below 2 years of age. When cholesterol levels are very high and presumed or known to be genetic, children above 8–10 years of age may benefit from statin therapy; however, the dosing should be conservative. Routine health monitoring should include assessment of growth and development and annual liver functions. Bile acid sequestrants and ezetimibe are also approved for children. For homozygous familial hypercholesterolemia (HoFH), the only therapy available is lipoprotein apheresis (LA). LA is presently not available in India. Recently, US Federal Drug Agency has approved mipomersen and lomitapide aimed at reducing cholesterol in HoFH.

Genetically determined dyslipidemia
Familial hypercholesterolemia
Lipoprotein apheresis
[Full Text]
Print this Article
Back to main page
  • Original Article
    Coronary artery disease risk factors distribution in cities versus urban and rural population of Karnataka
    -Dr Rajith KS*
    abstract text full text
  • Review Article
    Interventions to improve medication adherence in heart failure—A systematic review
    -Roberta L Fulton*, RGN, MSc; Thilo KroIl
    abstract text full text
  • Updates on Statins
    full text
  • News and Views
    full text
  • Forthcoming Events
    full text
  • American Society of Hypertension Annual Meeting 2017 (ASH 2017)
    To be held on Sep 13-16, 2017, San Francisco
  • American Society of Nuclear Cardiology 22nd Annual Scientific Session 2017 (ASNC 2017)
    To be held on Sep 14-17, 2017, Kansas City
  • Heart Failure Society of America 21st Annual Scientific Meeting 2017 (HFSA 2017)
    To be held on Sep 16-19, 2017, Texas
  • Global Cardio Diabetes Conclave 2017 (GCDC 2017)
    To be held on Sep 29—Oct 01, 2017, Chennai
Journal of Preventive Cardiology
Print ISSN: 2249-4308
Online ISSN: 2277-6559
Frequency: Quarterly
Email This
  [ Separate multiple email addresses with commas (Limit is 10). ]